Our results show the relevance of astrocyte atrophy in human AD which are equivalent to the observed in animal models, suggesting that in the human pathology, astrocyte atrophy is fundamental to the cognitive and mnesic alterations in early and late onset of AD contributing to neuronal damage and CNS dysfunction shown by cytoskeletal alterations—GFAP—and metabolic dysfunctions—GS—(Eid et al. 2012; Rodríguez et al. 2016, 2023). The gene discussed is GFAP; the disease is Alzheimer disease.